ReviewFrontiers in public health2025
Risk factors for severe COVID-19 outcomes in the Asia-Pacific region: a literature review.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies.Human vaccines & immunotherapeutics · 2026Review
- Article
- COVID-19 vaccination remains essential for healthcare professionals: clinical evidence from a Polish cross-sectional study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This comprehensive synthesis of severe COVID-19 risk factors specific to the Asia-Pacific (APAC) region addresses gaps in previous global studies, which often overlook regional demographic, epidemiological, and healthcare system variations. Three databases (PubMed, Ovid MedLine, Scopus) and two preprint platforms (BioRxiv, MedRxiv) were searched between December 1, 2019, and March 31, 2023. English-language publications from 11 APAC countries/regions (Australia, Hong Kong, Japan, Macau, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam) reporting conditions associated with severe COVID-19 outcomes in adults (aged ≥16 years) were included. Of 295 publications screened, 123 met inclusion criteria, mostly from South Korea (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.